$123.56 0.00 (0.00%)
5:53 EST ZTS Stock Quote Delayed 15 Minutes
Previous Close $123.56
Market Cap 59.79B
PE Ratio 62.09
Volume (Avg. Vol.) 1
Day's Range 123.56 - 123.56
52-Week Range 78.90 - 130.20
Dividend & Yield 0.38 (0.31%)
ZTS Stock Predictions, Articles, and Zoetis News
- From InvestorPlace
- From the Web
These health and beauty names are struggling at the moment — and their 3 big stock charts suggest the trend could get worse.
Both bulls and bears are converging on the latest geopolitical news items, wrestling for control of global markets. Given the uncertainties involved, protecting yourself with these safe stocks to buy seems like the most reasonable strategy.
ZTS stock is higher by roughly 30% year-to-date, but it is also extremely overbought. Traders can eye Zoetis for a mean-reversion move lower.
The stock charts of NRG, WFC and ZTS deserve some technical scrutiny on this week's hump-day, as each is getting close to a bigger move.
This morning I am recommending a bullish trade on Zoetis (NYSE:ZTS), a $44.5 billion company that discovers, develops, manufactures, and sells animal health medicines and vaccines.
The stock charts of Zoetis, News Corp and SCANA Corporation deserve a second, trading-oriented look on Wednesday morning.
General Electric being removed from the Dow reminds us that businesses can come and go. Here are seven stocks to buy I’d like to see in the Dow.
Abaxis (ABAX) stock was flying high Wednesday on news that Zoetis (ZTS) is acquiring it for $2.00 billion, or $83 per share.
We present four large cap drug companies, which are expected to repeat their last year’s industry beating performance in 2018. Compare Brokers...
The best healthcare stocks to buy now are those that are safe no matter when the American Health Care Act is passed, or what it looks like.
Nine notable dividend stocks raised their payouts last week, including Realty Income (O) and CVS Health (CVS). Here's what you need to know.
The following stocks were moving the Manufacturing sector today.
Eight notable dividend stocks raised their payouts last week, including Mastercard (MA) and Zoetis (ZTS). Here's what you need to know.
P/E isn't the only way to suss out disasters in the making. Here, free cash flow will lead us to some loser S&P 500 stocks to get rid of.
This week, 4 Pharmaceuticals stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").
The grades of 3 Pharmaceuticals stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
From Seeking Alpha
From Analyst Ratings
In a report released yesterday, Michael Ryskin from Merrill Lynch maintained a Hold rating on Zoetis (ZTS – Research Report), with a price target of $125.00. The company’s shares closed last Monday at $119.74. According to TipRanks.com, Ryskin is ranked #3804 out of 5722 analysts. Currently, the analyst consensus on Zoetis is a Strong Buy
Navellier RatingsPowered by Portfolio Grader